| dc.description.abstract | Purpose: This study aims to evaluate the predictive value of the pretreatment,metabolic,and diffusion parameters of a primary tumor assessed with PET/MR on patientclinical outcomes.Methods: Retrospective evaluation was performed using PET/MR image data setsacquired using the single tracer injection dual imaging of 68 histologically proven headand neck cancer patients 4 weeks before receiving definitive chemoradiotherapy (CRT).PET/MR was performed before the CRT and 12 weeks after the CRT for responseevaluation. Image data (PET and MRI diffusion-weighted imaging [DWI]) was used tospecify the maximum standard uptake value, the peak lean body mass corrected,SUVmax, the metabolic tumor volume, the total lesion glycolysis (SUVmax, SULpeak, MTV,and TLG), and the mean apparent diffusion coefficient (ADCmean) of the primary tumor.Based on the results of the therapeutic response evaluation, two patient subgroups werecreated: one with a viable tumor and another without. Metabolic and diffusion data,from the pretreatment PET/MR and the therapeutic response, were correlated usingSpearman’s correlation coefficient and Wilcoxon’s test.Results: After completing the CRT, a viable residual tumor was detectedin 36/68 (53%) cases, and 32/68 (47%) patients showed complete remission.However, no significant correlation was found between the pretreatment parameter,ADCmean (p = 0.88), and the therapeutic success. The PET parameters, SUVmaxand SULpeak, MTV, and TLG (p = 0.032, p = 0.01, p < 0.0001, p =0.0004) were statistically significantly different between the two patient subgroups. Conclusion: This study found that MRI-based (ADCmean) data from FDG PET/MRpretreatment could not be used to predict therapeutic response although the PETparameters SUVmax, SULpeak, MTV, and TLG proved to be more useful; thus, theirinclusion in risk stratification may also be of additional value. | |
